Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LoDoCo2 trial of low-dose colchicine for secondary prevention in stable coronary artery disease
NL-OMON50634Phase 3Active, not recruiting
- Sponsor
- WorldCare
- Start
- Oct 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis and atherosclerosis comparing Colchicine with Placebo (2 arms). Primary endpoints: Primary endpoint (original), Primary endpoint (protocol v2.6) and 1 more. Started Oct 2016; status: active, not recruiting.
02
Drugs
colchicine
03
Conditions
coronary arteriosclerosisatherosclerosis
Beyond the preview
Go deeper on NL-OMON50634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50634.